A PCT patent application from Terran Biosciences was just published covering their discovery of novel salts and polymorphs of the compound 4-OH-DiPT, adding another layer of IP intrigue around the lesser-known but potentially important compound.
Salts and Solid Forms of 4-Hydroxy-N,N-Diisopropyltryptamine Hemi-Glutarate and Hemi-Succinate was filed by Terran Biosciences and has claims on salts and polymorphs of 4-OH-DiPT, the same compound that both Mindset Pharma and Reunion Neuroscience have applied for patent claims on.
4-HO-DiPT is a psilocybin-like compound initially researched by the Shulgins and noted for its intense effects and shorter onset and trip time. Reunion and Mindset have been competing over patent claims on this drug, with Reunion recently suing Mindset Pharma over its competing patent.
Terran has been quite busy expanding its development portfolio and IP strategy
with several recent announcements (see below). This recent publication marks another milestone from Terran’s chemistry team who have built a robust solid-state chemistry platform. So while companies like Reunion and Mindset Pharma have been publicly dueling over the IP around this compound, it appears that Terran had been working on making advances to the compound’s chemistry and developing these novel approaches that, to our knowledge, others have not yet pursued.While Terran is developing many compounds in-house, they have announced that they’ve made large data packages and IP portfolios available for licensing and partnerships to help advance the psychedelic industry as a whole, which would certainly be of interest to other companies looking to accelerate the development of their pipelines.
